Anavex Life Sciences Corp (AVXL)

[sokol]

Sixteen out of twenty one PDD clinical trial sites in Spain are now reported active. I believe it is likely Anavex stock will trade “in the box” until we hear news from Spain that confirms or disaffirms the 148 weeks result. If we obtain positive news from the Spanish PDD trial, it will help pave the way for an licensing early approval of AVXL 2-73 for treatment of dementia in Australia and the European Union. Australia and the European Union have regulations that make this possible as I have posted before.

Organizations within Australia and the European Union are keenly aware of the Spanish PDD trial. For example, I received a response from the European Parkinson’s Disease Association that says “thank you for contacting the EPDA and for sending us these interesting news – we are already aware of the Anavex clinical trial which we hope will lead to concrete improvements in the treatment of Parkinson’s.” If our news from Spain leads to any improvement in treatment of PD, European Organizations and Dag Aarsland, MD, PhD (see today's announcement) will help with licensing and approval of AVXL 2-73.

We may do a licensing agreement with a partner pre-approval. Aarsland Played a role in the licensing of rivastigmine for Parkinsonian dementia as announced today.

My guess is that the good or bad news that moves the share price out of the box will occur in early 2019. In the meantime, the PDD trial is moving along because we have gone from twelve to sixteen active sites within the last week or so.